Skip to main content
SpringerLink
Log in
Book cover

Geriatric Oncology pp 353–363Cite as

Drug Interactions in Aging and Cancer

  • Reference work entry
  • First Online:

  • 696 Accesses

Abstract

Potential drug interactions (PDIs) can lead to adverse drug events (ADEs), which can be a source of potential morbidity, disability, and mortality among older adults. Older adults with cancer may be more susceptible to the negative impact of PDIs due to increased medications warranted as part of their cancer treatment (including symptom management and supportive care for the treatment plan). Polypharmacy is a geriatric syndrome that has led to increased complications among older adults with and without cancer and increases the risk of both PDIs and ADEs. Although several PDIs can be of unclear clinical significance when encountered, they may be more of an issue with competing medications used for comorbidities that face older adults with cancer. Moreover, this risk may be further augmented when the cancer treatment regimen is orally administered. The consequences of these types of PDIs may have more significant “downstream” effects on treatment adherence and persistence. However, as more anticancer drugs become available and adopted into clinical practice (particularly oral agents), additional studies will need to address PDIs within the dynamic landscape of cancer therapeutics and their impact on older adults with cancer who are at increased risk of toxicities.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–46.

    Article  Google Scholar 

  • Benoist GE, Hendriks RJ, Mulders PF, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55:1369–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beuscart JB, Pont LG, Thevelin S, et al. A systemic review of the outcomes reported in the trials of medication review in older patients need for a core outcome set. Br J Clin Pharmacol. 2016. https://doi.org/10.1111/bcp.13197.

  • Buajordet I, Ebbesen J, Erikssen J, et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001;250:327–41.

    Article  CAS  PubMed  Google Scholar 

  • Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;265:2002–12.

    Article  Google Scholar 

  • Clauson KA, Polen HH, Marsh WA. Clinical decision-support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy. 2007;27:1651–8.

    Article  PubMed  Google Scholar 

  • De Zwart L, Snoeys J, De Jong J, et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 2016;100:548–57.

    Article  PubMed  CAS  Google Scholar 

  • Del Giglio A, Miranda V, Fede A, et al. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Clin Oncol. 2009;27(15_suppl):e20656.

    Google Scholar 

  • Deliens C, Deliens G, Filleul O, et al. Drugs prescribed for patients hospitalized in a geriatric oncology unit: potentially inappropriate medications and impact of a clinical pharmacist. J Geriatr Oncol. 2016;7:463–70.

    Article  PubMed  Google Scholar 

  • Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behavior in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107:904–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Elliot K, Tooze JA, Geller R, et al. The prognostic important of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38:1184–90.

    Article  PubMed  PubMed Central  Google Scholar 

  • Flood KL, Carroll MB, Le CV, et al. Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother. 2009;7:151–8.

    Article  PubMed  Google Scholar 

  • Gay C, Toulet D, Le Corre P. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: a focus on cytochrome P450 transporters and acid suppression therapy. Hematol Oncol. 2016. https://doi.org/10.1002/hon.2335.

  • Gerard S, Brechemier D, Lefort A, et al. Body composition and anti-neoplastic treatment in adult and older subjects—a systematic review. J Nutr Health Aging. 2016;20:878–88.

    Article  CAS  PubMed  Google Scholar 

  • Girre V, Arkoub H, Puts MTE, et al. Potential drug interactions in elderly cancer patients. Crit Rev Hematol Oncol. 2011;78:220–6.

    Article  CAS  Google Scholar 

  • Hajjar ER, Hanlon JT, Artz MB, et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother. 2003;1:82–9.

    Article  PubMed  Google Scholar 

  • Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–51.

    Article  PubMed  Google Scholar 

  • Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci. 2006;61:511–5.

    Article  PubMed  Google Scholar 

  • Hoody DW, Beckett CF, Zielenski C, et al. Quality of drug information database research for clinical decision support. Int J Clin Pharm. 2011;33:599–602.

    Article  PubMed  Google Scholar 

  • Korc-Grodzicki B, Boparai MK, Lichmtan SM. Prescribing for older patients with cancer. Clin Adv Hematol Oncol. 2014;12:309–18.

    PubMed  Google Scholar 

  • Lambert Kuhn E, Leveque D, Lioure B, et al. Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. J Clin Pharm Ther. 2016;41:104–5.

    Article  CAS  PubMed  Google Scholar 

  • LeBlanc TW, McNewil MJ, Kamal AH, et al. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015;16:e333–41.

    Article  PubMed  Google Scholar 

  • Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15:507–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014;62:1505–12.

    Article  PubMed  PubMed Central  Google Scholar 

  • Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy. Expert Opin Drug Saf. 2014;13:57–65.

    Article  PubMed  Google Scholar 

  • Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm. 1986;43:1709–14.

    CAS  PubMed  Google Scholar 

  • Millic M, Foster A, Rihawi K, et al. Tablet burden in patients with metastatic breast cancer. Eur J Cancer. 2016;55:1–6.

    Article  Google Scholar 

  • Mohile SG, Fan L, Reeve E, et al. Association of cancer with geriatric syndromes in older Medicare beneficiaries. J Clin Oncol. 2011;29:1458–64.

    Article  PubMed  PubMed Central  Google Scholar 

  • Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33:1453–9.

    Article  PubMed  Google Scholar 

  • O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.

    Article  PubMed  Google Scholar 

  • Popa MA, Wallace KJ, Brunello A, et al. Potential drug interactions and chemotoxicity in older adults receiving cancer chemotherapy. J Geriatr Oncol. 2014;5:307–14.

    Article  PubMed  PubMed Central  Google Scholar 

  • Prithviraj GK, Koroukian S, Margevicius S, et al. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol. 2012;3:228–37.

    Article  PubMed  PubMed Central  Google Scholar 

  • Puts MT, Monette J, Girre V, et al. Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs Aging. 2010;27:559–72.

    Article  CAS  PubMed  Google Scholar 

  • Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20:1907–12.

    Article  CAS  PubMed  Google Scholar 

  • Riechelmann RP, Girardi D. Drug interactions in cancer patients: a hidden risk? J Res Pharm Pract. 2016;5:77–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Riechelmann RP, Moreira F, Smaletz O, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–90.

    Article  PubMed  Google Scholar 

  • Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600.

    Article  PubMed  Google Scholar 

  • Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.

    Article  PubMed  Google Scholar 

  • Saverno KR, Hines LE, Warholak TL, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc. 2011;18:32–7.

    Article  PubMed  Google Scholar 

  • Schmader KE, Hanlon JT. The mediation appropriateness index at 20: where it started, where it has been, and where it is going. Drugs Aging. 2013;30:893–900.

    Article  PubMed  Google Scholar 

  • Sharma M, Loh KP, Nightingale G, et al. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7:346–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32:169–75.

    Article  CAS  PubMed  Google Scholar 

  • Turner JP, Jamsen KM, Shakib S, et al. Polypharmacy cut-points in older people with cancer: how many medications is too many? Support Care Cancer. 2016a;24:1831–40.

    Article  PubMed  Google Scholar 

  • Turner JP, Shakib S, Bell JS. Is my older cancer patient on too many medications? J Geriatr Oncol. 2016b. https://doi.org/10.1016/j.jgo.2016.10.003.

  • Van Leeuwen RW, Brundel DH, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108:1071–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Van Leeuwen RW, Jansman FG, van den Bemt PM, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26:992–7.

    Article  PubMed  Google Scholar 

  • Van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34:1309–14.

    Article  PubMed  CAS  Google Scholar 

  • Wong SF, Bounthavong M, Nguyen CP, et al. Outcome assessment and cost avoidance of an oral chemotherapy management clinic. J Natl Compr Cancer Netw. 2016;14:279–85.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, University of Rochester, Rochester, NY, USA

    Ronald J. Maggiore

Authors
  1. Ronald J. Maggiore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald J. Maggiore .

Editor information

Editors and Affiliations

  1. Senior Adult Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA

    Martine Extermann

Section Editor information

  1. Department of Supportive Care Medicine, City of Hope Duarte - Comprehensive Cancer Center, Duarte, USA

    William Dale

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Maggiore, R.J. (2020). Drug Interactions in Aging and Cancer. In: Extermann, M. (eds) Geriatric Oncology . Springer, Cham. https://doi.org/10.1007/978-3-319-57415-8_55

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-57415-8_55

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-57414-1

  • Online ISBN: 978-3-319-57415-8

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation